221 related articles for article (PubMed ID: 25973680)
1. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.
Yang Y; Xu H; Shen J; Yang Y; Wu S; Xiao J; Xu Y; Liu XY; Chu L
Cell Death Dis; 2015 May; 6(5):e1760. PubMed ID: 25973680
[TBL] [Abstract][Full Text] [Related]
2. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.
Yang Y; Xu H; Huang W; Ding M; Xiao J; Yang D; Li H; Liu XY; Chu L
J Cell Mol Med; 2015 May; 19(5):915-23. PubMed ID: 25683371
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer.
Wang H; Cai Z; Yang F; Luo J; Satoh M; Arai Y; Li D
Urology; 2014 Feb; 83(2):508.e13-9. PubMed ID: 24315309
[TBL] [Abstract][Full Text] [Related]
4. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter.
Jacob D; Bahra M; Schumacher G; Neuhaus P; Fang B
Anticancer Res; 2004; 24(5A):3075-9. PubMed ID: 15517918
[TBL] [Abstract][Full Text] [Related]
6. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
7. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
8. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter].
Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B
Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959
[TBL] [Abstract][Full Text] [Related]
9. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
[TBL] [Abstract][Full Text] [Related]
10. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
[TBL] [Abstract][Full Text] [Related]
11. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.
Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X
Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010
[TBL] [Abstract][Full Text] [Related]
12. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
[TBL] [Abstract][Full Text] [Related]
13. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
14. Fiber-modified adenovirus-mediated suicide gene therapy can efficiently eliminate bladder cancer cells in vitro and in vivo.
Wang DG; Zhao MJ; Liu YQ; Liu XW; Niu HT; Song YF; Tian YX
Oncotarget; 2016 Nov; 7(44):71710-71717. PubMed ID: 27687590
[TBL] [Abstract][Full Text] [Related]
15. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
17. Improved gene transfer into bladder cancer cells using adenovirus vector containing RGD motif.
Hiwasa K; Nagaya H; Terao S; Acharya B; Hamada K; Mizuguchi H; Gotoh A
Anticancer Res; 2012 Aug; 32(8):3137-40. PubMed ID: 22843884
[TBL] [Abstract][Full Text] [Related]
18. Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.
Shen YH; Yang F; Wang H; Cai ZJ; Xu YP; Zhao A; Su Y; Zhang G; Zhu SX
PLoS One; 2016; 11(1):e0147173. PubMed ID: 26799485
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.
Zhai Z; Wang Z; Fu S; Lu J; Wang F; Li R; Zhang H; Li S; Hou Z; Wang H; Rodriguez R
Gene Ther; 2012 Nov; 19(11):1065-74. PubMed ID: 22218302
[TBL] [Abstract][Full Text] [Related]
20. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
